155 related articles for article (PubMed ID: 30755452)
1. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
3. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
[TBL] [Abstract][Full Text] [Related]
4. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
5. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Ketelhut R; Bramlage P
Clin Drug Investig; 2010; 30(5):301-11. PubMed ID: 20384386
[TBL] [Abstract][Full Text] [Related]
7. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
8. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Hanrahan JP; de Boer IH; Bakris GL; Wilson PJ; Wakefield JD; Seferovic JP; Chickering JG; Chien YT; Carlson K; Cressman MD; Currie MG; Milne GT; Profy AT
Clin J Am Soc Nephrol; 2020 Dec; 16(1):59-69. PubMed ID: 33328269
[TBL] [Abstract][Full Text] [Related]
10. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
Matsuno K; Kuroda S; Tanaka S; Nakamichi H; Kagawa T; Koumura E
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):607-614. PubMed ID: 29845723
[TBL] [Abstract][Full Text] [Related]
12. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects.
Matsuno K; Tanaka S; Hashimoto T; Nakamichi H; Kagawa T; Koumura E
J Clin Pharmacol; 2018 Nov; 58(11):1516-1524. PubMed ID: 29733435
[TBL] [Abstract][Full Text] [Related]
15. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
[TBL] [Abstract][Full Text] [Related]
16. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Haneda M; Kikkawa R; Sakai H; Kawamori R;
Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
Mogensen CE; Neldam S; Tikkanen I; Oren S; Viskoper R; Watts RW; Cooper ME
BMJ; 2000 Dec; 321(7274):1440-4. PubMed ID: 11110735
[TBL] [Abstract][Full Text] [Related]
20. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
